Financial Contrast: Masimo Corporation (MASI) and Tactile Systems Technology (TCMD)

Masimo Corporation (NASDAQ: MASI) and Tactile Systems Technology (NASDAQ:TCMD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitabiliy, valuation, analyst recommendations, dividends, earnings and risk.

Valuation and Earnings

This table compares Masimo Corporation and Tactile Systems Technology’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Masimo Corporation $730.06 million 5.84 $182.11 million $6.14 13.36
Tactile Systems Technology $97.23 million 5.45 $3.09 million $0.25 125.20

Masimo Corporation has higher revenue and earnings than Tactile Systems Technology. Masimo Corporation is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.


This table compares Masimo Corporation and Tactile Systems Technology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Masimo Corporation 45.90% 23.45% 16.22%
Tactile Systems Technology 4.97% 3.05% 2.54%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Masimo Corporation and Tactile Systems Technology, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Masimo Corporation 0 3 3 0 2.50
Tactile Systems Technology 0 0 4 0 3.00

Masimo Corporation presently has a consensus price target of $96.25, suggesting a potential upside of 17.32%. Tactile Systems Technology has a consensus price target of $33.00, suggesting a potential upside of 5.43%. Given Masimo Corporation’s higher probable upside, equities analysts plainly believe Masimo Corporation is more favorable than Tactile Systems Technology.

Insider and Institutional Ownership

84.4% of Masimo Corporation shares are held by institutional investors. Comparatively, 34.7% of Tactile Systems Technology shares are held by institutional investors. 16.6% of Masimo Corporation shares are held by insiders. Comparatively, 49.9% of Tactile Systems Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


Masimo Corporation beats Tactile Systems Technology on 9 of the 13 factors compared between the two stocks.

Masimo Corporation Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include non-invasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical, brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor, and the Radius-7 wearable wireless patient monitor. It offers Patient SafetyNet remote patient surveillance monitoring system, which allows patients to be monitored through a personal computer-based monitor or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.

What are top analysts saying about Masimo Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Masimo Corporation and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit